Skip to main content
Erschienen in: Tumor Biology 2/2016

26.08.2015 | Original Article

Evaluation of GWAS-identified SNPs at 6p22 with neuroblastoma susceptibility in a Chinese population

verfasst von: Jing He, Ruizhong Zhang, Yan Zou, Jinhong Zhu, Tianyou Yang, Fenghua Wang, Huimin Xia

Erschienen in: Tumor Biology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Previous genome-wide association studies (GWASs) have reported that three single nucleotide polymorphisms (SNPs) (rs6939340 A>G, rs4712653 T>C, and rs9295536 C>A) located at 6p22 locus were associated with neuroblastoma susceptibility for Caucasian descent. We conducted this hospital-based case-control study with 201 neuroblastoma patients and 531 controls to investigate the association between these three SNPs in the FLJ22536 gene with neuroblastoma susceptibility in the Chinese Han population. The odds ratio (OR) and 95 % confidence interval (CI) were calculated to estimate the strength of the association using unconditional logistic regression model. We found that the rs6939340 A allele carriers were associated with significantly decreased neuroblastoma susceptibility (AG vs. GG: adjusted OR = 0.54, 95 % CI = 0.38–0.77; AA vs. GG: adjusted OR = 0.49, 95 % CI = 0.25–0.93; and AA/AG vs. GG: adjusted OR = 0.53, 95 % CI = 0.38–0.74) after adjustment for age and gender. The protective association between variant allele and neuroblastoma susceptibility was also observed for the rs4712653 and rs9295536 polymorphisms. Moreover, we found that subjects carrying one or more protective genotypes had a much lower neuroblastoma susceptibility than non-carriers (adjusted OR = 0.60, 95 % CI = 0.43–0.83). Our study verified that the associations between all of the three SNPs in the 6p22 locus are associated with neuroblastoma susceptibility in the Chinese subjects. Further prospective multicenter studies with different ethnicities and larger sample size are needed to validate our findings.
Literatur
1.
2.
Zurück zum Zitat Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, et al. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol. 1997;19:428–32.CrossRefPubMed Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, et al. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol. 1997;19:428–32.CrossRefPubMed
3.
Zurück zum Zitat Bao PP, Li K, Wu CX, Huang ZZ, Wang CF, et al. Recent incidences and trends of childhood malignant solid tumors in Shanghai, 2002–2010. Zhonghua Er Ke Za Zhi. 2013;51:288–94.PubMed Bao PP, Li K, Wu CX, Huang ZZ, Wang CF, et al. Recent incidences and trends of childhood malignant solid tumors in Shanghai, 2002–2010. Zhonghua Er Ke Za Zhi. 2013;51:288–94.PubMed
4.
Zurück zum Zitat Knudson Jr AG, Strong LC. Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet. 1972;24:514–32.PubMedPubMedCentral Knudson Jr AG, Strong LC. Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet. 1972;24:514–32.PubMedPubMedCentral
5.
Zurück zum Zitat Capasso M, Diskin SJ. Genetics and genomics of neuroblastoma. Cancer Treat Res. 2010;155:65–84.CrossRefPubMed Capasso M, Diskin SJ. Genetics and genomics of neuroblastoma. Cancer Treat Res. 2010;155:65–84.CrossRefPubMed
6.
Zurück zum Zitat Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation and its contribution to complex traits. Nat Rev Genet. 2009;10:241–51.CrossRefPubMed Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation and its contribution to complex traits. Nat Rev Genet. 2009;10:241–51.CrossRefPubMed
8.
Zurück zum Zitat Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008;358:2585–93.CrossRefPubMedPubMedCentral Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008;358:2585–93.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009;41:718–23.CrossRefPubMedPubMedCentral Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009;41:718–23.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat le Nguyen B, Diskin SJ, Capasso M, Wang K, Diamond MA, et al. Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. PLoS Genet. 2011;7:e1002026.CrossRefPubMedCentral le Nguyen B, Diskin SJ, Capasso M, Wang K, Diamond MA, et al. Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. PLoS Genet. 2011;7:e1002026.CrossRefPubMedCentral
11.
Zurück zum Zitat Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature. 2011;469:216–20.CrossRefPubMed Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature. 2011;469:216–20.CrossRefPubMed
12.
Zurück zum Zitat Diskin SJ, Capasso M, Schnepp RW, Cole KA, Attiyeh EF, et al. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet. 2012;44:1126–30.CrossRefPubMedPubMedCentral Diskin SJ, Capasso M, Schnepp RW, Cole KA, Attiyeh EF, et al. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet. 2012;44:1126–30.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Latorre V, Diskin SJ, Diamond MA, Zhang H, Hakonarson H, et al. Replication of neuroblastoma SNP association at the BARD1 locus in African-Americans. Cancer Epidemiol Biomarkers Prev. 2012;21:658–63.CrossRefPubMedPubMedCentral Latorre V, Diskin SJ, Diamond MA, Zhang H, Hakonarson H, et al. Replication of neuroblastoma SNP association at the BARD1 locus in African-Americans. Cancer Epidemiol Biomarkers Prev. 2012;21:658–63.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Capasso M, Diskin SJ, Totaro F, Longo L, De Mariano M, et al. Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. Carcinogenesis. 2013;34:605–11.CrossRefPubMed Capasso M, Diskin SJ, Totaro F, Longo L, De Mariano M, et al. Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. Carcinogenesis. 2013;34:605–11.CrossRefPubMed
15.
Zurück zum Zitat He J, Qiu LX, Wang MY, Hua RX, Zhang RX, et al. Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet. 2012;131:1235–44.CrossRefPubMed He J, Qiu LX, Wang MY, Hua RX, Zhang RX, et al. Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet. 2012;131:1235–44.CrossRefPubMed
16.
Zurück zum Zitat He J, Wang MY, Qiu LX, Zhu ML, Shi TY, et al. Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population. Mol Carcinog. 2013;52 Suppl 1:E70–9.CrossRefPubMed He J, Wang MY, Qiu LX, Zhu ML, Shi TY, et al. Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population. Mol Carcinog. 2013;52 Suppl 1:E70–9.CrossRefPubMed
17.
Zurück zum Zitat Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.CrossRefPubMed Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.CrossRefPubMed
19.
Zurück zum Zitat Russell MR, Penikis A, Oldridge DA, Alvarez-Dominguez JR, McDaniel L, et al. CASC15-S is a tumor suppressor lncRNA at the 6p22 neuroblastoma susceptibility locus. Cancer Res. 2015;75:3155–66.CrossRefPubMedPubMedCentral Russell MR, Penikis A, Oldridge DA, Alvarez-Dominguez JR, McDaniel L, et al. CASC15-S is a tumor suppressor lncRNA at the 6p22 neuroblastoma susceptibility locus. Cancer Res. 2015;75:3155–66.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Xue W, Zhu M, Wang Y, He J, Zheng L. Association between PLCE1 rs2274223 A>G polymorphism and cancer risk: proof from a meta-analysis. Sci Rep. 2015;5:7986.CrossRefPubMedPubMedCentral Xue W, Zhu M, Wang Y, He J, Zheng L. Association between PLCE1 rs2274223 A>G polymorphism and cancer risk: proof from a meta-analysis. Sci Rep. 2015;5:7986.CrossRefPubMedPubMedCentral
Metadaten
Titel
Evaluation of GWAS-identified SNPs at 6p22 with neuroblastoma susceptibility in a Chinese population
verfasst von
Jing He
Ruizhong Zhang
Yan Zou
Jinhong Zhu
Tianyou Yang
Fenghua Wang
Huimin Xia
Publikationsdatum
26.08.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3936-7

Weitere Artikel der Ausgabe 2/2016

Tumor Biology 2/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.